Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus R P MYCIN.
E-MYCIN E vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic